Targeting a Poor Prognosis Marker for Tumor Therapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$150,480.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA144614-01A1
Award Id:
95894
Agency Tracking Number:
CA144614
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
10451 Roselle St #300, SAN DIEGO, CA, 92121
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
010081909
Principal Investigator:
DOUGLASLAPPI
(858) 642-1988
TARGETING@ATSBIO.COM
Business Contact:
DENISEHIGGINS
() -
ats@atsbio.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Targeting a Poor Prognosis Marker for Tumor Therapy Summary The purpose of this proposal is to develop a medical treatment for the elimination of metastatic cancers. According to the National Cancer Institute, the s urvival rate for many types of cancer has improved in recent years; however, it is still the second leading cause of death in the United States. This proposal describes an experimental design to verify the suitability of basigin-2 (also known as CD147 or E MMPRIN) as a cell surface target for an innovative tumor therapy. This project will accomplish important goals in determining the suitability of basigin-2 for further drug development: 1) Provide proof of internalization of the target moiety (basigin-2) b y using an antibody to basigin-2, and 2) Demonstrate that there is specificity, both in terms of greater ability to target the tumor over normal (lower level) expression and that anti-basigin is specific for the target. In this Phase I grant, a cytotoxin w ill be produced that has two components: 1) anti-basigin to specifically target and internalize into basigin-2 positive cells, and 2) a toxin that will inhibit protein synthesis upon internalization by the antibody. This innovative approach will create a m olecule that targets tumor cells, metastasis and angiogenesis, with the idea to not just slow tumor cell proliferation, but to eliminate tumors. PUBLIC HEALTH RELEVANCE: Targeting a Poor Prognosis Marker for Tumor Therapy Narrative This project begins a new direction of potential treatment for a wide range of deadly cancers by targeting a molecule that is expressed on the surface of many tumor types with poor prognosis. While it is proposed to directly target these tumors through targeting the m olecule, basigin-2, targeting of tumor metastasis and angiogenesis is also indicated, since basigin-2 plays important roles in those dangerous processes. The project builds on current technologies, but puts several together to go in a new, innovative direc tion.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government